We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

195 hedge funds and large institutions have $2.15B invested in Kite Pharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 82 increasing their positions, 42 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 19

95% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 42

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

14% more capital invested

Capital invested by funds: $1.88B → $2.15B (+$267M)

13% more funds holding

Funds holding: 173195 (+22)

23% less call options, than puts

Call options by funds: $68.3M | Put options by funds: $88.7M

Holders
195
Holders Change
+22
Holders Change %
+12.72%
% of All Funds
5.2%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
43
Increased
82
Reduced
42
Closed
19
Calls
$68.3M
Puts
$88.7M
Net Calls
-$20.4M
Net Calls Change
-$39.9M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
76
UBS Group
Switzerland
$2.33M -$4.88M -87,509 -68%
SAM
77
Shikiar Asset Management
New York
$2.18M -$22.3K -400 -1%
Citadel Advisors
78
Citadel Advisors
Florida
$2.14M -$8.45M -151,596 -80%
ProShare Advisors
79
ProShare Advisors
Maryland
$2.04M -$354K -6,347 -15%
TAM
80
Tocqueville Asset Management
New York
$2.01M +$100K +1,800 +5%
Morgan Stanley
81
Morgan Stanley
New York
$1.88M +$783K +14,050 +72%
Barclays
82
Barclays
United Kingdom
$1.88M +$1.87M +33,631 New
LCM
83
Laurion Capital Management
New York
$1.86M +$1.86M +33,300 New
MOACM
84
Mutual of America Capital Management
New York
$1.63M +$724K +13,000 +80%
GL
85
GLG LLC
New York
$1.61M +$209K +3,750 +15%
MLICM
86
Metropolitan Life Insurance Company (MetLife)
New York
$1.56M -$26.7K -480 -2%
SG Americas Securities
87
SG Americas Securities
New York
$1.55M -$3.17M -56,957 -67%
Wells Fargo
88
Wells Fargo
California
$1.55M -$55.6K -998 -3%
Baird Financial Group
89
Baird Financial Group
Wisconsin
$1.54M -$149K -2,671 -9%
SEC
90
Seven Eight Capital
New York
$1.51M +$1.51M +27,018 New
Manulife (Manufacturers Life Insurance)
91
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.5M +$4.9K +88 +0.3%
PAM
92
Panagora Asset Management
Massachusetts
$1.5M +$1.5M +26,866 New
BG
93
BlackRock Group
United Kingdom
$1.49M -$157K -2,824 -10%
OAM
94
Oxford Asset Management
United Kingdom
$1.42M +$1.42M +25,453 New
PPA
95
Parametric Portfolio Associates
Washington
$1.42M +$350K +6,274 +33%
PA
96
Profund Advisors
Maryland
$1.34M -$21.5K -385 -2%
AIG
97
American International Group
New York
$1.26M +$1.89K +34 +0.2%
State Board of Administration of Florida Retirement System
98
State Board of Administration of Florida Retirement System
Florida
$1.22M +$49K +880 +4%
RJFSA
99
Raymond James Financial Services Advisors
Florida
$1.19M +$925K +16,610 +350%
FO
100
FT Options
Illinois
$1.18M +$1.18M +21,134 New

KITE Hedge Fund Activity: Q3 2016 in Review

195 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2016, worth a combined $2.15B — up 14% from $1.88B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new KITE positions and 19 closed out — a net gain of 24 holders — while 82 added to existing stakes and 42 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $39.9M. The largest seller was Viking Global Investors, cutting an estimated $112M.

  • 195 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2016, up from 173 in Q2 2016.
  • Funds reported $2.15B of Kite Pharma, Inc. stock for Q3 2016, up 14% quarter-over-quarter.
  • 43 funds opened new Kite Pharma, Inc. positions in Q3 2016 and 19 closed out, a net change of +24 holders.
  • The largest Kite Pharma, Inc. buyer in Q3 2016 was Waddell & Reed Financial, an estimated $39.9M added.
  • The largest Kite Pharma, Inc. seller in Q3 2016 was Viking Global Investors, an estimated $112M sold.

Based on aggregated 13F filings for Q3 2016.